Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 12, Issue 1, 2013, Pages 54-59

  Uluer, Ahmet Z ^a,b   Waltz, David A ^a   Kalish, Leslie A ^a   Adams, Summer ^a   Gerard, Craig ^a,b   Ericson, Dawn A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Amiloride; Burkholderia cepacia complex; Burkholderia dolosa; Cystic fibrosis; Tobramycin

Indexed keywords

AMILORIDE; BRONCHODILATING AGENT; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; BRONCHOSPASM; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA DOLOSA; CLINICAL ARTICLE; CYSTIC FIBROSIS; FEMALE; HUMAN; LIVER TOXICITY; LUNG FUNCTION; MALE; NEPHROTOXICITY; OTOTOXICITY; RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; AMILORIDE; ANTI-BACTERIAL AGENTS; BURKHOLDERIA INFECTIONS; CHRONIC DISEASE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; HUMANS; TOBRAMYCIN; TREATMENT FAILURE;

EID: 84870729431     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.06.006     Document Type: Article

References (28)

1. Davis P.B., Drumm M., Konstan M.W. Cystic fibrosis. Am J Respir Crit Care Med 1996, 154(5):1229-1256.
2. Available from: http://www.cff.org/LivingWithCF/QualityImprovement/PatientRegistryReport/.
3. Frangolias D.D., Mahenthiralingham E., Rae S., Raboud J.M., Davidson A.G., Wittmann R., et al. Burkholderia cepacia in cystic fibrosis. Variable disease course. Am J Respir Crit Care Med 1999, 160(5 Pt 1):1572-1577.
4. Isles A., Maclusky I., Corey M., et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984, 104(2):206-210.
5. Tablan O.C., Chorba T.L., Schidlow D.V., et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985, 107(3):382-387.
6. Tablan O.C., Martone W.J., Doershuk C.F., et al. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes. Chest 1987, 91(4):527-532.
7. Whiteford M.L., Wilkinson J.D., McColl J.H., Conlon F.M., Michie J.R., Evans T.J., et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 1995, 50(11):1194-1198.
8. Lipuma J.J. Burkholderia cepacia complex as human pathogens. J Nematol 2003, 35(2):212-217.
9. Kalish L.A., Waltz D.A., Dovey M., Potter-Bynoe G., McAdam A.J., Lipuma J.J., et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006, 173(4):421-425.
10. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340(1):23-30.
11. Knowles M.R., Stutts M.J., Spock A., Fischer N., Gatzy J.T., Boucher R.C. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983, 221(4615):1067-1070.
12. Boucher R.C., Stutts M.J., Knowles M.R., Cantley L., Gatzy J.T. Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 1986, 78(5):1245-1252.
13. Knowles M., Murray G., Shallal J., Askin F., Ranga V., Gatzy J., et al. Bioelectric properties and ion flow across excised human bronchi. J Appl Physiol 1984, 56(4):868-877.
14. Knowles M., Gatzy J., Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981, 305(25):1489-1495.
15. App E.M., King M., Helfesrieder R., Kohler D., Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990, 141(3):605-612.
16. Knowles M.R., Church N.L., Waltner W.E., Yankaskas J.R., Gilligan P., King M., et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990, 322(17):1189-1194.
17. Middleton P.G., Kidd T.J., Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex. Eur Respir J 2005, 26(2):305-308.
18. Noone P.G., Regnis J.A., Liu X., Brouwer K.L., Robinson M., Edwards L., et al. Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. Chest 1997, 112(5):1283-1290.
19. Pons G., Marchand M.C., d'Athis P. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group. Pediatr Pulmonol 2000, 30(1):25-31.
20. Graham A., Hasani A., Alton E.W., Martin G.P., Marriott C., Hodson M.E., et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993, 6(9):1243-1248.
21. Viaca A., Bignamini E. Concentration of inhaled amiloride in cystic fibrosis. Lancet 1996, 347(9008):1126.
22. Cohn R.C., Rudzienski L. In vitro suppression of Pseudomonas cepacia after limited exposure to subinhibitory concentrations of amiloride and 5-(N, N-hexamethylene) amiloride. Pediatr Pulmonol 1994, 17(6):366-369.
23. Cohn R.C., Rudzienski L. Substituted amines synergistic with tobramycin against Burkholderia cepacia in vitro. Chemotherapy 1997, 43(2):100-107.
24. Cohn R.C., Jacobs M., Aronoff S.C. In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1988, 32(3):395-396.
25. Cohn R.C., Aronoff S.C. The effect of sodium on amiloride-tobramycin synergy in Pseudomonas cepacia. J Lab Clin Med 1989, 114(6):724-727.
26. Jones A.M., Dodd M.E., Govan J.R., Barcus V., Doherty C.J., Morris J., et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004, 59(11):948-951.
27. Henry B., Aussage P., Grosskopf C., Goehrs J.M. Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual Life Res 2003, 12(1):63-76.
28. Ball R., Brownlee K.G., Duff A.J., Denton M., Conway S.P., Lee T.W. Can Burkholderia cepacia complex be eradicated with nebulised amiloride and TOBI?. J Cyst Fibros 2010, 9(1):73-74.